Clinical laboratories are increasingly adopting solid phase extraction for Therapeutic Drug Monitoring (TDM) and the diagnosis of metabolic disorders. SPE allows for the precise measurement of drug levels in a patient’s blood, ensuring that dosages remain within the therapeutic window and minimizing the risk of toxicity. This is particularly important for medications with narrow therapeutic indices, such as immunosuppressants and anti-epileptics. The ability of SPE to provide a clean, concentrated sample is essential for the high-sensitivity requirements of clinical mass spectrometry.

According to the Solid Phase Extraction Market analysis, the clinical laboratory segment is undergoing a shift toward "on-line SPE" systems. These systems are directly coupled to the LC-MS/MS instrument, allowing the extraction and analysis to occur in a single, continuous workflow. This "on-line" approach reduces sample handling, minimizes the risk of contamination, and provides faster results—a critical factor in acute clinical settings. As personalized medicine becomes more prevalent, the integration of SPE into routine clinical workflows will be essential for delivering data-driven patient care.